{
    "xml": "<topic id=\"PHP2258\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/trifluoperazine\" basename=\"trifluoperazine\" title=\"TRIFLUOPERAZINE\">\n<title>TRIFLUOPERAZINE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_383\" namespace=\"/interactions/list-of-drug-interactions/antipsychotics/phenothiazines/trifluoperazine\">Trifluoperazine</xref>\n</p>\n<data name=\"vtmid\">71699007</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_182743901\" title=\"Antipsychotics (first-generation)\">Antipsychotics (first-generation)</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34569\" title=\"ANTIPSYCHOTIC DRUGS\" namespace=\"/drug-classes/antipsychotic-drugs\">ANTIPSYCHOTIC DRUGS</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">   </data>\n</data>\r\n</body>\n<topic id=\"PHP48262\" outputclass=\"indicationsAndDose\" rev=\"1.28\" parent=\"/drugs/trifluoperazine\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Schizophrenia and other psychoses</p>\n<p outputclass=\"therapeuticIndication\">Short-term adjunctive management of psychomotor agitation, excitement, and violent or dangerously impulsive behaviour</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 5&#8239;mg twice daily for 1 week, then increased in steps of 5&#8239;mg daily, dose then to be increased at intervals of 3 days, according to response.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Elderly</p>\n<p>Initially up to 2.5&#8239;mg twice daily for 1 week, then increased in steps of 5&#8239;mg daily, dose then to be increased at intervals of 3 days, according to response.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Short-term adjunctive management of severe anxiety</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>2&#8211;4&#8239;mg daily in divided doses, increased if necessary to 6&#8239;mg daily.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Elderly</p>\n<p>Up to 2&#8239;mg daily in divided doses, increased if necessary to 6&#8239;mg daily.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Severe nausea and vomiting</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>2&#8211;4&#8239;mg daily in divided doses; maximum 6&#8239;mg per day.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48348\" outputclass=\"contraindications\" rev=\"1.8\" parent=\"/drugs/trifluoperazine\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">CNS depression</ph>; <ph outputclass=\"contraindication\">comatose states</ph>; <ph outputclass=\"contraindication\">phaeochromocytoma</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48209\" outputclass=\"sideEffects\" rev=\"1.20\" parent=\"/drugs/trifluoperazine\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Anorexia</ph>; <ph outputclass=\"sideEffect\">dystonic reactions</ph>; <ph outputclass=\"sideEffect\">muscle weakness</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p>Extrapyramidal symptoms are more frequent, especially at doses exceeding 6&#8239;mg daily.</p>\n<p>Phenothiazines can all induce acute dystonic reactions such as facial and skeletal muscle spasms and oculogyric crises; children (especially girls, young women, and those under 10&#8239;kg) are particularly susceptible.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48249\" outputclass=\"pregnancy\" parent=\"/drugs/trifluoperazine\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Extrapyramidal effects and withdrawal syndrome have been reported occasionally in the neonate when antipsychotic drugs are taken during the third trimester of pregnancy.</p>\n<p>Following maternal use of antipsychotic drugs in the third trimester, neonates should be monitored for symptoms including agitation, hypertonia, hypotonia, tremor, drowsiness, feeding problems, and respiratory distress.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48407\" outputclass=\"breastFeeding\" parent=\"/drugs/trifluoperazine\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>There is limited information available on the short- and long-term effects of antipsychotic drugs on the breast-fed infant.</p>\n<p>\n<i>Animal</i> studies indicate possible adverse effects of antipsychotic medicines on the developing nervous system.</p>\n<p>Chronic treatment with antipsychotic drugs whilst breast-feeding should be avoided unless absolutely necessary.</p>\n<p>Phenothiazine derivatives are sometimes used in breast-feeding women for short-term treatment of nausea and vomiting.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48299\" outputclass=\"hepaticImpairment\" parent=\"/drugs/trifluoperazine\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Can precipitate coma; phenothiazines are hepatotoxic.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48226\" outputclass=\"renalImpairment\" parent=\"/drugs/trifluoperazine\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Start with small doses in severe renal impairment because of increased cerebral sensitivity.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48178\" outputclass=\"monitoringRequirements\" parent=\"/drugs/trifluoperazine\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Trifluoperazine does not affect blood pressure to the same extent as other antipsychotic drugs and so blood pressure monitoring is not mandatory for this drug.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP2258-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/trifluoperazine\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74734\" title=\"Tablet\" namespace=\"/drugs/trifluoperazine/tablet\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74748\" title=\"Oral solution\" namespace=\"/drugs/trifluoperazine/oral-solution\">Oral solution</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78155\" namespace=\"/treatment-summaries/psychoses-and-related-disorders\" title=\"Psychoses and related disorders\" count=\"2\" rel=\"backlink\">Psychoses and related disorders</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78221\" namespace=\"/treatment-summaries/nausea-and-labyrinth-disorders\" title=\"Nausea and labyrinth disorders\" count=\"1\" rel=\"backlink\">Nausea and labyrinth disorders</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_383\" namespace=\"/interactions/list-of-drug-interactions/antipsychotics/phenothiazines/trifluoperazine\" title=\"Trifluoperazine\" count=\"1\" rel=\"link\">Trifluoperazine</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34569\" namespace=\"/drug-classes/antipsychotic-drugs\" title=\"ANTIPSYCHOTIC DRUGS\" count=\"1\" rel=\"link\">ANTIPSYCHOTIC DRUGS</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74734\" namespace=\"/drugs/trifluoperazine/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74748\" namespace=\"/drugs/trifluoperazine/oral-solution\" title=\"Oral solution\" count=\"1\" rel=\"link\">Oral solution</xref>\n</links>\n</topic>",
    "id": "PHP2258",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/trifluoperazine",
    "basename": "trifluoperazine",
    "title": "TRIFLUOPERAZINE",
    "interactants": [
        {
            "id": "bnf_int_383",
            "label": "Trifluoperazine"
        }
    ],
    "vtmid": "71699007",
    "drugClassification": [
        "Antipsychotics (first-generation)"
    ],
    "inheritsFromClass": [
        "ANTIPSYCHOTIC DRUGS"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Schizophrenia and other psychoses",
                        "html": "Schizophrenia and other psychoses"
                    },
                    {
                        "textContent": "Short-term adjunctive management of psychomotor agitation, excitement, and violent or dangerously impulsive behaviour",
                        "html": "Short-term adjunctive management of psychomotor agitation, excitement, and violent or dangerously impulsive behaviour"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "Initially 5 mg twice daily for 1 week, then increased in steps of 5 mg daily, dose then to be increased at intervals of 3 days, according to response.",
                        "html": "<p>Initially 5&#8239;mg twice daily for 1 week, then increased in steps of 5&#8239;mg daily, dose then to be increased at intervals of 3 days, according to response.</p>"
                    },
                    {
                        "textContent": "Initially up to 2.5 mg twice daily for 1 week, then increased in steps of 5 mg daily, dose then to be increased at intervals of 3 days, according to response.",
                        "html": "<p>Initially up to 2.5&#8239;mg twice daily for 1 week, then increased in steps of 5&#8239;mg daily, dose then to be increased at intervals of 3 days, according to response.</p>",
                        "ageGroup": "elderly"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Short-term adjunctive management of severe anxiety",
                        "html": "Short-term adjunctive management of severe anxiety"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "2&#8211;4 mg daily in divided doses, increased if necessary to 6 mg daily.",
                        "html": "<p>2&#8211;4&#8239;mg daily in divided doses, increased if necessary to 6&#8239;mg daily.</p>"
                    },
                    {
                        "textContent": "Up to 2 mg daily in divided doses, increased if necessary to 6 mg daily.",
                        "html": "<p>Up to 2&#8239;mg daily in divided doses, increased if necessary to 6&#8239;mg daily.</p>",
                        "ageGroup": "elderly"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Severe nausea and vomiting",
                        "html": "Severe nausea and vomiting"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "2&#8211;4 mg daily in divided doses; maximum 6 mg per day.",
                        "html": "<p>2&#8211;4&#8239;mg daily in divided doses; maximum 6&#8239;mg per day.</p>"
                    }
                ]
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "CNS depression",
                "html": "CNS depression"
            },
            {
                "type": "contraindications",
                "textContent": "comatose states",
                "html": "comatose states"
            },
            {
                "type": "contraindications",
                "textContent": "phaeochromocytoma",
                "html": "phaeochromocytoma"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Anorexia",
                        "html": "Anorexia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "dystonic reactions",
                        "html": "dystonic reactions",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "muscle weakness",
                        "html": "muscle weakness",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "textContent": "Extrapyramidal symptoms are more frequent, especially at doses exceeding 6 mg daily.\n\nPhenothiazines can all induce acute dystonic reactions such as facial and skeletal muscle spasms and oculogyric crises; children (especially girls, young women, and those under 10 kg) are particularly susceptible.",
                "html": "<p>Extrapyramidal symptoms are more frequent, especially at doses exceeding 6&#8239;mg daily.</p><p>Phenothiazines can all induce acute dystonic reactions such as facial and skeletal muscle spasms and oculogyric crises; children (especially girls, young women, and those under 10&#8239;kg) are particularly susceptible.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Extrapyramidal effects and withdrawal syndrome have been reported occasionally in the neonate when antipsychotic drugs are taken during the third trimester of pregnancy.\n\nFollowing maternal use of antipsychotic drugs in the third trimester, neonates should be monitored for symptoms including agitation, hypertonia, hypotonia, tremor, drowsiness, feeding problems, and respiratory distress.",
                "html": "<p>Extrapyramidal effects and withdrawal syndrome have been reported occasionally in the neonate when antipsychotic drugs are taken during the third trimester of pregnancy.</p><p>Following maternal use of antipsychotic drugs in the third trimester, neonates should be monitored for symptoms including agitation, hypertonia, hypotonia, tremor, drowsiness, feeding problems, and respiratory distress.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "There is limited information available on the short- and long-term effects of antipsychotic drugs on the breast-fed infant.\n\nAnimal studies indicate possible adverse effects of antipsychotic medicines on the developing nervous system.\n\nChronic treatment with antipsychotic drugs whilst breast-feeding should be avoided unless absolutely necessary.\n\nPhenothiazine derivatives are sometimes used in breast-feeding women for short-term treatment of nausea and vomiting.",
                "html": "<p>There is limited information available on the short- and long-term effects of antipsychotic drugs on the breast-fed infant.</p><p>\n<i>Animal</i> studies indicate possible adverse effects of antipsychotic medicines on the developing nervous system.</p><p>Chronic treatment with antipsychotic drugs whilst breast-feeding should be avoided unless absolutely necessary.</p><p>Phenothiazine derivatives are sometimes used in breast-feeding women for short-term treatment of nausea and vomiting.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Can precipitate coma; phenothiazines are hepatotoxic.",
                "html": "<p>Can precipitate coma; phenothiazines are hepatotoxic.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Start with small doses in severe renal impairment because of increased cerebral sensitivity.",
                "html": "<p>Start with small doses in severe renal impairment because of increased cerebral sensitivity.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Trifluoperazine does not affect blood pressure to the same extent as other antipsychotic drugs and so blood pressure monitoring is not mandatory for this drug.",
                "html": "<p>Trifluoperazine does not affect blood pressure to the same extent as other antipsychotic drugs and so blood pressure monitoring is not mandatory for this drug.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP74734",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP74748",
                "label": "Oral solution",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78155",
                "label": "Psychoses and related disorders",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78221",
                "label": "Nausea and labyrinth disorders",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_383",
                "label": "Trifluoperazine",
                "type": "interaction"
            }
        ],
        "drugClass": [
            {
                "id": "PHP34569",
                "label": "ANTIPSYCHOTIC DRUGS",
                "type": "drugClass"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP74734",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP74748",
                "label": "Oral solution",
                "type": "medicinalForm"
            }
        ]
    }
}